Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
31665497
DOI
10.1093/rheumatology/kez427
PII: 5609873
Knihovny.cz E-resources
- Keywords
- DAPSA28, DAS28, TNFi, drug survival, effectiveness, epidemiology, psoriatic arthritis, register, response, spondyloarthritis,
- MeSH
- Antirheumatic Agents therapeutic use MeSH
- Databases, Factual MeSH
- Adult MeSH
- Tumor Necrosis Factor Inhibitors therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Patient Acceptance of Health Care * MeSH
- Prospective Studies MeSH
- Arthritis, Psoriatic drug therapy MeSH
- Registries MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antirheumatic Agents MeSH
- Tumor Necrosis Factor Inhibitors MeSH
OBJECTIVE: To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naïve patients with PsA. METHODS: Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis ⩽4] and ACR criteria for 20% improvement (ACR20)/ACR50/ACR70 were calculated, including LUNDEX adjustment. RESULTS: Overall, 14 261 patients with PsA initiated a first TNFi. Considerable heterogeneity of baseline characteristics between registries was observed. The median 12-month retention rate (95% CI) was 77% (76, 78%), ranging from 68 to 90% across registries. Overall, DAS28/28 joint Disease Activity index for Psoriatic Arthritis remission rates at 6 months were 56%/27% (LUNDEX: 45%/22%). Six-month ACR20/50/70 responses were 53%/38%/22%, respectively. In patients initiating a first TNFi after 2009 with registered fulfilment of ClASsification for Psoriatic ARthritis (CASPAR) criteria (n = 1980) or registered one or more swollen joint at baseline (n = 5803), the retention rates and response rates were similar to those found overall. CONCLUSION: Approximately half of >14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database of PsA patients treated in routine care was demonstrated, offering unique opportunities for research with real-world data.
Amsterdam Rheumatology and immunology Center Academic Medical Center Amsterdam
biorx si and the Department of Rheumatology University Medical Centre Ljubljana Slovenia Ljubljana
Center of Rheumatic Diseases University of Medicine and Pharmacy Bucharest Romania
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
Department of Rheumatology Diakonhjemmet Hospital Oslo Norway
Department of Rheumatology Geneva University Hospital Geneva Switzerland
GISEA registry Rheumatology Unit DETO University of Bari Bari Italy
Inflammation Center Department of Rheumatology Helsinki University Hospital Helsinki Finland
Research Unit Spanish Society of Rheumatology Madrid Spain
ROB FIN Registry Helsinki University and Helsinki University Hospital Helsinki Finland
TURKBIO Registry and Division of Rheumatology School of Medicine Dokuz Eylul University Izmir Turkey
University of Iceland Faculty of Medicine and Landspitali University Hospital Reykjavik Iceland
References provided by Crossref.org